Kodiak manages to score a win for its Eylea rival — but the major test is still ahead
Kodiak Sciences may have failed to show that its anti-VEGF drug is just as good as Regeneron’s Eylea for wet AMD, but the biotech is keeping the pressure on.
In a new Phase III study involving patients with retinal vein occlusion (RVO) — a blinding condition that stems from vein blockage in the eye — KSI-301, which is dosed every two months, proved non-inferior in visual acuity gains to a monthly regimen of Eylea.
Unlock this article instantly by becoming a free subscriber.
You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.